Aprea Therapeutics (APRE) Projected to Release Earnings on Tuesday

Aprea Therapeutics (NASDAQ:APRE) will likely be issuing its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $0.2530 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 9:30 AM ET.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%. On average, analysts expect Aprea Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aprea Therapeutics Stock Performance

APRE traded up $0.00 during midday trading on Tuesday, reaching $0.60. 32,965 shares of the company were exchanged, compared to its average volume of 1,059,956. The stock has a market capitalization of $7.44 million, a P/E ratio of -0.39 and a beta of 1.52. Aprea Therapeutics has a one year low of $0.55 and a one year high of $1.83. The stock’s 50-day simple moving average is $0.74 and its 200 day simple moving average is $0.78.

Analyst Ratings Changes

APRE has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. Wedbush cut their target price on shares of Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Finally, Oppenheimer assumed coverage on shares of Aprea Therapeutics in a research report on Thursday, May 7th. They set an “outperform” rating and a $5.00 price target on the stock. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $4.07.

Hedge Funds Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Jane Street Group LLC purchased a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned 0.67% of Aprea Therapeutics at the end of the most recent reporting period. 34.19% of the stock is owned by institutional investors and hedge funds.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.